Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19
- PMID: 32341442
- PMCID: PMC7184165
- DOI: 10.1038/s41440-020-0455-8
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19
Abstract
The rapid spread of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an ongoing pandemic of coronavirus disease 2019 (COVID-19). Recently, angiotensin-converting enzyme 2 (ACE2) has been shown to be a functional receptor for SARS-CoV-2 to enter host target cells. Given that angiotensin receptor blockers (ARBs) and an ACE inhibitor (ACEI) upregulated ACE2 expression in animal studies, the concern might arise regarding whether ARBs and ACEIs would increase the morbidity and mortality of COVID-19. On the other hand, animal data suggested a potential protective effect of ARBs against COVID-19 pneumonia because an ARB prevented the aggravation of acute lung injury in mice infected with SARS-CoV, which is closely related to SARS-CoV-2. Importantly, however, there is no clinical or experimental evidence supporting that ARBs and ACEIs either augment the susceptibility to SARS-CoV-2 or aggravate the severity and outcomes of COVID-19 at present. Until further data are available, it is recommended that ARB and ACEI medications be continued for the treatment of patients with cardiovascular disease and hypertension, especially those at high risk, according to guideline-directed medical therapy based on the currently available evidence.
Keywords: Acute lung injury; Angiotensin II type-1 receptor; Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitor; Severe acute respiratory syndrome coronavirus 2.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence.Clin Pharmacol Ther. 2020 Aug;108(2):236-241. doi: 10.1002/cpt.1863. Epub 2020 May 10. Clin Pharmacol Ther. 2020. PMID: 32320478 Free PMC article. Review.
-
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15. Ann Intern Med. 2020. Update in: Ann Intern Med. 2021 Feb;174(2):W25-W29. doi: 10.7326/L20-1446. Update in: Ann Intern Med. 2021 Jun;174(6):W54-W55. doi: 10.7326/L21-0223. PMID: 32422062 Free PMC article. Updated.
-
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4. Curr Cardiol Rep. 2020. PMID: 32291526 Free PMC article. Review.
-
Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.J Am Soc Nephrol. 2020 Sep;31(9):1941-1943. doi: 10.1681/ASN.2020050667. Epub 2020 Jul 15. J Am Soc Nephrol. 2020. PMID: 32669323 Free PMC article. No abstract available.
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15. Diabetes Metab Syndr. 2020. PMID: 32311651 Free PMC article.
Cited by
-
Assessment of the liver with two-dimensional shear wave elastography following COVID-19 infection: A pilot study.Australas J Ultrasound Med. 2024 May 6;27(3):167-173. doi: 10.1002/ajum.12390. eCollection 2024 Aug. Australas J Ultrasound Med. 2024. PMID: 39328255
-
Genetic Polymorphisms of Angiotensin-Converting Enzyme 1 (ACE1) and ACE2 Associated With Severe Acute Respiratory Syndrome COVID-19 in the Palestinian Population.Cureus. 2024 Aug 24;16(8):e67670. doi: 10.7759/cureus.67670. eCollection 2024 Aug. Cureus. 2024. PMID: 39318909 Free PMC article.
-
Do angiotensin-converting enzyme inhibitors not reduce the risk of pneumonia?Hypertens Res. 2024 Aug 16. doi: 10.1038/s41440-024-01848-8. Online ahead of print. Hypertens Res. 2024. PMID: 39152258 No abstract available.
-
Shadow left by COVID-19 pandemic on the future.Hypertens Res. 2024 Aug 1. doi: 10.1038/s41440-024-01789-2. Online ahead of print. Hypertens Res. 2024. PMID: 39090180 No abstract available.
-
A retrospective prognostic evaluation using unsupervised learning in the treatment of COVID-19 patients with hypertension treated with ACEI/ARB drugs.PeerJ. 2024 May 13;12:e17340. doi: 10.7717/peerj.17340. eCollection 2024. PeerJ. 2024. PMID: 38756444 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous